Voyager Therapeutics (VYGR) Total Non-Current Liabilities (2014 - 2024)

Voyager Therapeutics has disclosed Total Non-Current Liabilities across 11 years of filings, most recently posting $56.4 million for Q3 2024.

• Total Non-Current Liabilities for Q3 2024 came in at $56.4 million, down 43.36% year-over-year; the trailing twelve-month figure through Sep 2024 was $56.4 million (down 43.36% YoY), and the FY2023 annual result was $96.9 million, up 22.55% from the prior year.
• Total Non-Current Liabilities came in at $56.4 million for Q3 2024 at Voyager Therapeutics, down from $59.6 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $211.8 million in Q1 2020 to a low of $56.3 million in Q3 2021.
• The 5-year median for Total Non-Current Liabilities is $80.6 million (2022), against an average of $91.5 million.
• Across the five-year window, Total Non-Current Liabilities sank 72.44% in 2021 and soared 88.68% in 2022, its largest moves.
• Voyager Therapeutics' Total Non-Current Liabilities stood at $62.9 million in 2020, then retreated by 5.83% to $59.2 million in 2021, then surged by 33.54% to $79.0 million in 2022, then rose by 22.55% to $96.9 million in 2023, then sank by 41.81% to $56.4 million in 2024.
• The last three Total Non-Current Liabilities figures came in at $56.4 million (Q3 2024), $59.6 million (Q2 2024), and $85.7 million (Q1 2024), per Business Quant data.